Solid Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

De winst van Solid Biosciences is gedaald met een gemiddeld jaarlijks percentage van -19%, terwijl de winst van de Biotechs -industrie jaarlijks groeide met 33.8%. De inkomsten zijn daalde met een gemiddeld percentage van 63.2% per jaar.

Belangrijke informatie

-19.01%

Groei van de winst

42.11%

Groei van de winst per aandeel

Biotechs Groei van de industrie	17.04%
Inkomstengroei	-63.23%
Rendement op eigen vermogen	-51.26%
Nettomarge	n/a
Laatste winstupdate	31 Mar 2026

Recente prestatie-updates uit het verleden

Recent updates

Seeking Alpha • Mar 12

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

Summary Solid Biosciences is repositioning itself in a scrutinized space with promising early-stage trial results for its lead candidate, SGT-003. Recent events involving Sarepta Therapeutics have unfairly impacted Solid's stock price, creating a potential recovery opportunity if Sarepta clarifies the isolated nature of the patient's death. Solid's pipeline includes SGT-003 for DMD, SGT-212 for Friedreich’s ataxia, and SGT-501 for CPVT, with promising early data and no serious adverse effects. Despite risks, Solid's strong financial position and potential market disruption with SGT-003 make it a Buy, assuming continued safety and favorable Sarepta developments. Read the full article on Seeking Alpha

Seeking Alpha • Jan 21

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Summary Initiation of phase 1b study, using gene therapy SGT-212 for the treatment of patients with Friedreich's Ataxia, expected 2nd half of 2025. The global Friedreich's Ataxia market is expected to grow to $7.56 billion in 2034. Data from the first 3 patients of the phase 1/2 INSPIRE DUCHENNE study, using SGT-003 for the treatment of patients with Duchenne Muscular Dystrophy, expected in Q1 of 2025. SGT-501 is another gene therapy product candidate with an expected IND filing in the 1st half of 2025 for the treatment of patients with RYR2-mediated Catecholaminergic Polymorphic Ventricular Tachycardia. Read the full article on Seeking Alpha

Analyseartikel • Nov 16

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analyseartikel • Jul 26

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Solid...

Seeking Alpha • Apr 10

Buy Solid Biosciences: Unpacking Its Main Value Driver

Summary Solid Biosciences is focused on gene therapy innovation for neuromuscular and cardiac conditions. Their flagship drug therapy for Duchenne muscular dystrophy (DMD) is expected to be tested in Q2 2024. SLDB recently received additional liquidity from a PIPE investment, improving its risk-reward equation. SLDB's valuation appears undervalued relative to its peers, which is why I ultimately lean bullish post-PIPE investment. Read the full article on Seeking Alpha

Seeking Alpha • Jan 17

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Summary IND SGT-003 gene therapy cleared for phase 1/2 testing: First patient dosing expected late Q1 2024 with biomarker/functional data expected Q3 of 2024. The global Duchenne Muscular Dystrophy drugs market is expected to reach $27.4 billion by 2030. Solid Biosciences might be able to overcome gene therapy competitors in the DMD space with its own proprietary capsid of AAV-SLB101, which may end up having better transgene expression. An IND filing to begin a phase 1 study using SGT-501 for the treatment of patients with catecholaminergic polymorphic ventricular tachycardia is expected by Q1 of 2025. Read the full article on Seeking Alpha

Seeking Alpha • Sep 30

Solid Biosciences to acquire gene therapy company AavantiBio

Life sciences company Solid Biosciences (NASDAQ:SLDB) will acquire the gene therapy company AavantiBio. The combined entity aims to advance a portfolio of neuromuscular and cardiac programs. The merger is subject to an approval by the shareholders of Solid. Post the transaction, the current CEO of AavantiBio, Bo Cumbo, will assume the role of president and CEO of Solid Biosciences. In support of the acquisition, SLDB has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $75M private placement. The private placement is expected to close concurrently with the closing of the merger in Q4. The combined entity is expected to have total cash and investments of ~$215M post the closing of the merger. SLDB shares were trading +17.47% pre-market. Source: Press Release

Analyseartikel • Apr 30

Analysts Have Lowered Expectations For Solid Biosciences Inc. (NASDAQ:SLDB) After Its Latest Results

It's shaping up to be a tough period for Solid Biosciences Inc. ( NASDAQ:SLDB ), which a week ago released some...

Analyseartikel • Apr 28

Some Analysts Just Cut Their Solid Biosciences Inc. (NASDAQ:SLDB) Estimates

The latest analyst coverage could presage a bad day for Solid Biosciences Inc. ( NASDAQ:SLDB ), with the analysts...

Analyseartikel • Mar 17

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Opbrengsten en kosten

Hoe Solid Biosciences geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.

Inkomsten en omzetgeschiedenis

NasdaqGS:SLDB Opbrengsten, kosten en inkomsten (USD Millions )
Datum	Inkomsten	Inkomsten	G+A Uitgaven	R&D-uitgaven
31 Mar 26	0	-192	41	156
31 Dec 25	0	-174	39	140
30 Sep 25	0	-167	37	133
30 Jun 25	0	-154	35	121
31 Mar 25	0	-140	34	108
31 Dec 24	0	-125	33	96
30 Sep 24	0	-102	31	81
30 Jun 24	0	-91	30	70
31 Mar 24	0	-90	28	71
31 Dec 23	0	-96	28	77
30 Sep 23	0	-91	24	61
30 Jun 23	0	-90	24	44
31 Mar 23	6	-91	24	25
31 Dec 22	8	-86	24	0
30 Sep 22	11	-89	29	59
30 Jun 22	15	-87	29	59
31 Mar 22	12	-81	28	59
31 Dec 21	14	-72	27	0
30 Sep 21	10	-75	26	65
30 Jun 21	7	-78	24	65
31 Mar 21	3	-78	22	65
31 Dec 20	0	-88	22	65
30 Sep 20	0	-99	21	27
30 Jun 20	0	-107	23	50
31 Mar 20	0	-114	23	71
31 Dec 19	0	-117	25	95
30 Sep 19	0	-107	24	85
30 Jun 19	0	-97	21	77
31 Mar 19	0	-89	21	69
31 Dec 18	0	-75	18	58
30 Sep 18	0	-67	16	52
30 Jun 18	0	-62	15	48
31 Mar 18	0	-55	14	43
31 Dec 17	0	-39	15	40
30 Sep 17	0	-29	13	35
31 Dec 16	0	-17	5	20

Kwaliteitswinsten: SLDB is momenteel verliesgevend.

Groeiende winstmarge: SLDB is momenteel verliesgevend.

Analyse vrije kasstroom versus winst

Analyse van de winstgroei in het verleden

Winsttrend: SLDB is verliesgevend en de verliezen zijn de afgelopen 5 jaar toegenomen met een snelheid van 19% per jaar.

Versnelling van de groei: Het is niet mogelijk om de winstgroei van SLDB over het afgelopen jaar te vergelijken met het gemiddelde over de afgelopen vijf jaar, omdat het bedrijf momenteel verliesgevend is.

Winst versus industrie: SLDB is verlieslatend, waardoor het lastig is om de winstgroei van het afgelopen jaar te vergelijken met die van de Biotechs industrie ( 43% ).

Rendement op eigen vermogen

Hoge ROE: SLDB heeft een negatief Return on Equity ( -51.26% ), omdat het momenteel verliesgevend is.

Rendement op activa

Rendement op geïnvesteerd vermogen

Ontdek sterk presterende bedrijven uit het verleden

Bedrijfsanalyse en status van financiële gegevens

Gegevens	Laatst bijgewerkt (UTC-tijd)
Bedrijfsanalyse	2026/05/19 13:11
Aandelenkoers aan het einde van de dag	2026/05/19 00:00
Inkomsten	2026/03/31
Jaarlijkse inkomsten	2025/12/31

Gegevensbronnen

De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.

Pakket	Gegevens	Tijdframe	Voorbeeld Amerikaanse bron ^*
Financiële gegevens bedrijf	10 jaar	Resultatenrekening Kasstroomoverzicht Balans	SEC-formulier 10-K SEC-formulier 10-Q
Consensus schattingen analisten	+3 jaar	Financiële prognoses Koersdoelen analisten	Onderzoeksrapporten van analisten Blue Matrix
Marktprijzen	30 jaar	Aandelenprijzen Dividenden, splitsingen en acties	ICE Marktgegevens SEC-formulier S-1
Eigendom	10 jaar	Top aandeelhouders Handel met voorkennis	SEC-formulier 4 SEC-formulier 13D
Beheer	10 jaar	Leiderschapsteam Raad van bestuur	SEC-formulier 10-K SEC-formulier DEF 14A
Belangrijkste ontwikkelingen	10 jaar	Bedrijfsaankondigingen	SEC-formulier 8-K

^* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.

Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.

Analysemodel en Snowflake

Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.

Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.

Industrie en sector

Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.

Bronnen van analisten

Solid Biosciences Inc. wordt gevolgd door 22 analisten. 14 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.

Analist	Instelling
Timothy Chiang	BTIG
Kristen Kluska	Cantor Fitzgerald & Co.
Charles Duncan	Cantor Fitzgerald & Co.

Solid Biosciences Inkomsten in het verleden

Verleden criteriumcontroles 0/6

Belangrijke informatie

Recente prestatie-updates uit het verleden

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Solid Biosciences Inc. to Report Q1, 2022 Results on Apr 27, 2022

Recent updates

Solid Biosciences Doses First Participant in Phase 3 Impact Duchenne Clinical Trial Evaluating Sgt-003 in Duchenne Muscular Dystrophy

Solid Biosciences Inc., Annual General Meeting, Jun 10, 2026

New minor risk - Shareholder dilution

Solid Biosciences: Interim Data Lends Credibility For Q1 2026 Trial Start

Solid Biosciences Inc. Provides Interim Positive Clinical Update on Phase 1/2 Inspire Duchenne Trial

Solid Biosciences Inc. announced that it expects to receive $239.972139 million in funding from a group of investors

President notifies of intention to sell stock

Solid Biosciences Announces Positive Feedback from Type C Meeting with FDA for SGT-003 Gene Therapy for Duchenne Muscular Dystrophy

President recently sold US$315k worth of stock

President exercised options and sold US$517k worth of stock

Solid Biosciences Inc. Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid Aav-Slb101

Solid Biosciences Inc Receives FDA Orphan Drug Designation for SGT-212 Dual-Route Gene Therapy for the Treatment of Friedreich’s Ataxia

Insufficient new directors

Solid Biosciences Inc. Announces Duchenne Muscular Dystrophy Added to National Recommended Uniform Screening Panel by the U.S. Department of Health and Human Services

President notifies of intention to sell stock

Solid Biosciences Inc. Receives FDA Rare Pediatric Disease Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich's Ataxia

Solid Biosciences Inc. Receives Innovation Passport Designation Under the New UK Innovative Licensing and Access Pathway for SGT-003, an Investigational Gene Therapy for Duchenne Muscular Dystrophy

Solid Biosciences Inc. Provides Update on Inspire Duchenne Clinical Trial Progress and Planned Regulatory Discussions

We're Keeping An Eye On Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

New minor risk - Share price stability

Solid Biosciences Inc. Receives FDA Fast Track Designation for SGT-501 First-In-Class Gene Therapy for Catecholaminergic Polymorphic Ventricular Tachycardia

We're Not Very Worried About Solid Biosciences' (NASDAQ:SLDB) Cash Burn Rate

Solid Biosciences Inc. Announces FDA IND and Health Canada CTA Approval for First-In-Class Cardiac Gene Therapy to Treat Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Solid Biosciences Inc.(NasdaqGS:SLDB) dropped from Russell Small Cap Comp Growth Index

Price target decreased by 7.2% to US$15.50

Solid Biosciences Inc. to Present At the American Society of Gene and Cell Therapy's 28th Annual Meeting

Solid Biosciences Inc., Annual General Meeting, Jun 12, 2025

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space

New major risk - Share price stability

New major risk - Shareholder dilution

Solid Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $199.987556 million.

Solid Biosciences Reports Positive Initial Clinical Data from Next-Generation Duchenne Gene Therapy Candidate SGT-003

New minor risk - Share price stability

Solid Biosciences: Differentiating Factors Of SGT-212 To Set Itself Apart

Solid Biosciences Inc. Receives FDA Fast Track Designation for SGT-212 Dual Route of Administration Gene Therapy for Friedreich’s Ataxia

Solid Biosciences Inc. Announces FDA IND Clearance for First-In-Industry Dual Route of Administration Gene Therapy to Treat Both Neurologic and Cardiac Manifestations of Friedreich's Ataxia

President notifies of intention to sell stock

Is Solid Biosciences (NASDAQ:SLDB) In A Good Position To Invest In Growth?

Price target decreased by 9.0% to US$18.00

We Think Solid Biosciences (NASDAQ:SLDB) Can Afford To Drive Business Growth

Price target increased by 13% to US$19.78

Consensus revenue estimates increase by 123%

Solid Biosciences Inc. Announces Board Resignations

Solid Biosciences Inc., Annual General Meeting, Jun 11, 2024

Buy Solid Biosciences: Unpacking Its Main Value Driver

Solid Biosciences Inc. Receives Rare Pediatric Disease Designation from the FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate SGT-003

Consensus EPS estimates upgraded to US$2.79 loss

Solid Biosciences: DMD Treatment Advancement With Next-Generation Capsid

Solid Biosciences Inc. announced that it expects to receive $108.858551 million in funding from a group of investors

Solid Biosciences Announces IND Clearance by FDA for Duchenne Muscular Dystrophy Gene Therapy Candidate Sgt-003

Consensus revenue estimates decrease by 50%, EPS upgraded

New minor risk - Share price stability

Solid Biosciences Inc. Appoints Gabriel Brooks as Chief Medical Officer

Consensus revenue estimates decrease by 33%, EPS upgraded

New major risk - Revenue size

New minor risk - Market cap size

Solid Biosciences Inc. Announces Executive Changes

First quarter 2023 earnings released: US$1.54 loss per share (vs US$3.37 loss in 1Q 2022)

Full year 2022 earnings: EPS misses analyst expectations

Solid Biosciences Inc. and Phlox Therapeutics Announce Strategic Research Collaboration Focused on Accelerating the Development of New Therapies for Rare Cardiac Diseases

Solid Biosciences Appoints Kevin Tan as Chief Financial Officer

Solid Biosciences Inc. Announces Executive Changes

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Third quarter 2022 earnings released: US$2.71 loss per share (vs US$2.40 loss in 3Q 2021)

Consensus forecasts updated

Price target decreased to US$3.00

Solid Biosciences Inc. Reports Additional Preclinical Data Demonstrating that its Novel Capsid, AAV-SLB101, Provides Superior Transduction Efficiency and Enhanced Distribution to Skeletal Muscle